FINWIRES · TerminalLIVE
FINWIRES

Piper Sandler Downgrades Myriad Genetics to Underweight From Overweight

By

Myriad Genetics (MYGN) has an average rating of hold and mean price target of $3.34, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles